[A new drug and current strategy in the treatment of acute non-lymphocytic leukemia in adults].
Among new drugs being studied currently, AMSA and mitoxantrone have shown significant usefulness against acute non-lymphocytic leukemia in adults. Remission induction therapy consisting of daunomycin and cytosine arabinoside has been commonly selected as the first line of treatment and the complete remission rate obtained has exceeded 70%. Postremission therapy consolidation has been judged to be necessary while the clinical roles of maintenance and intensification remain to be clarified and appear to still require an investigational approach.
D000208:Acute Disease; D000328:Adult; D000609:Aminoacridines / Q000008:administration & dosage / Q000627:therapeutic use; D000677:Amsacrine; D000880:Anthraquinones / Q000008:administration & dosage / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D008942:Mitoxantrone
D000609:Aminoacridines; D000880:Anthraquinones; D000970:Antineoplastic Agents; D000677:Amsacrine; D003561:Cytarabine; D005047:Etoposide; D008942:Mitoxantrone